deaths (OS)progression or deaths (PFS)RFS/DFS

hepatocell cancer (HCC) hepatocell cancer (HCC)

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 - certainty unassessable-1%-

mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 ---

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus sorafenib
durvalumab plus tremelimumab vs. sorafenib 1 certainty unassessablestatistically conclusive-20% certainty unassessable-9%-

mHCC - 2nd line (L2) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 2nd line (L2)